StockData
iBio, Inc. logo

iBio, Inc. (IBIO) stock

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.80−0.00 (-0.11%)

Close on Nov 20, 2026Market cap $51.45MP/E –Yield –

iBio gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

iBio's gross profit for the twelve months ending Jun 30, 2022 was $2.17M, up 138.4% year over year. For fiscal 2022 it was $2.17M, up 138.4% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2022Jun 30, 2022$2.17M+138.4%
FY2021Jun 30, 2021$909.00K-2.8%
FY2020Jun 30, 2020$935.00K–

Quarterly gross profit

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2022CQ2 2022Jun 30, 2022$46.00K-90.7%
Q3 FY2022CQ1 2022Mar 31, 2022$1.90M+525.4%
Q4 FY2021CQ2 2021Jun 30, 2021$304.00K-63.0%
Q3 FY2021CQ1 2021Mar 31, 2021$272.00K+2620.0%
Q2 FY2021CQ4 2020Dec 31, 2020$494.00K–
Q1 FY2021CQ3 2020Sep 30, 2020$303.00K–
Q4 FY2020CQ2 2020Jun 30, 2020$821.00K–
Q3 FY2020CQ1 2020Mar 31, 2020$10.00K–

More iBio figures

See a number that looks wrong?